Solifenacin succinate

Drug interactions are possible if CYP450 inhibitors are given with solifenacin succinate (metabolized by 3A4 isoenzyme) or darifenacin (metabolized by 2D6 and 3A4 isoenzymes). 

Cardozo L. Randomized, double-blind placebo controlled trial of once daily antimuscar-inic agent solifenacin succinate in patients with overactive bladder. I Urol 2004 i 72 i9i9. 

Solifenacin Succinate Tablet For overactive bladder with urge urinary incontinence urgency urinary frequency... 

Chappie CR et al A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome Results of the STAR trial. Eur Urol 2005 48 464. [PMID 15990220]... 

Solifenacin succinate (Vesicare) was approved in late 2004 by FDA for the treatment of OAB with urge incontinence, nrgency, and urinary frequency. This agent was comprehensively reviewed and the data provided below come principally from thatpnblication. ... 

Solifenacin succinate is an anticholinergic agent, which is used in the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. 

Vesicare (Solifenacin succinate). Astellas Pharma Ltd, UK Summary of product characteristics, September 2005. 

VESIcare (Solifenacin succinate). GlaxoSmithKline. US Prescribing information, November 2004. 

Although the clinical relevance of this interaction has not been assessed, the manufacturers recommend that the daily dose of solifenacin succinate is limited to 5 mg if it is given with ketoconazole or other potent inhibitors of CYP3A4. The UK manufacturer specifically names itraconazole, nelfinavir and ritonavir. In addition, in patients with severe renal impairment or moderate hepatic impairment, the combined use of solifenacin and potent CYP3A4 inhibitors is contraindicated. For a list of clinically significant CYP3A4 inhibitors, see Table 1.4 , (p.6). 

---